SHKK(SH:900943)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 199,595,462.29, representing an increase of 11.50% compared to the same period last year [3] - The net profit attributable to shareholders for Q1 2023 was CNY 9,795,174.23, reflecting a growth of 16.06% year-over-year [3] - Basic earnings per share for Q1 2023 were CNY 0.040, up by 14.29% from the previous year [3] - Total operating revenue for Q1 2023 reached ¥199,595,462.29, an increase of 11.0% compared to ¥179,002,475.46 in Q1 2022 [11] - Net profit for Q1 2023 was ¥9,080,552.75, representing a 24.0% increase from ¥7,320,355.27 in Q1 2022 [11] - Earnings per share for Q1 2023 were ¥0.040, compared to ¥0.035 in Q1 2022, marking a 14.3% increase [11] Cash Flow - The net cash flow from operating activities was negative at CNY -24,761,380.76, indicating a significant cash outflow [3] - Cash flow from operating activities showed a net outflow of ¥24,761,380.76 in Q1 2023, worsening from a net outflow of ¥17,377,534.45 in Q1 2022 [14] - Investment activities resulted in a net cash outflow of ¥50,014,416.03 in Q1 2023, compared to a smaller outflow of ¥512,015.94 in Q1 2022 [14] - Financing activities also showed a net cash outflow of ¥3,732,580.00 in Q1 2023, an improvement from an outflow of ¥7,164,163.19 in Q1 2022 [14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,137,627,439.76, a decrease of 5.77% from the end of the previous year [3] - As of March 31, 2023, total assets amounted to ¥1,137,627,439.76, a decrease of approximately 5.77% from ¥1,207,255,505.50 on December 31, 2022 [8] - Current assets totaled ¥524,013,720.38, down 11.06% from ¥589,293,001.32 at the end of 2022 [8] - Total current liabilities were ¥358,026,106.61, a reduction of 17.73% from ¥435,213,299.44 [9] - The total liabilities amounted to ¥550,295,468.92, a decrease of 12.52% from ¥629,004,087.41 [9] Equity and Investments - The company's equity attributable to shareholders increased to ¥578,377,443.33, up from ¥568,582,269.10, reflecting a growth of 1.40% [9] - The company’s investment income increased by 129.23% compared to the previous year, attributed to gains from Shanghai Jing'an Pharmaceutical Co., Ltd. [5] - The company reported an increase in investment income to ¥1,358,685.13 in Q1 2023, up from ¥592,729.19 in Q1 2022 [11] Other Financial Metrics - The weighted average return on equity increased by 0.12 percentage points to 1.71% [3] - The company reported a significant increase in credit impairment losses by 425.94% due to a rise in bad debt provisions [5] - The company received government subsidies totaling CNY 5,547,800 during the reporting period, including CNY 3,847,900 on February 17, 2023 [7] - The company reported a decrease in inventory to ¥69,068,809.18, down 22.24% from ¥88,718,754.49 [8] - Cash and cash equivalents decreased to ¥222,422,833.06, a decline of 26.06% compared to ¥300,932,076.82 [8] - Accounts receivable stood at ¥150,113,420.39, down 9.23% from ¥165,407,141.33 [8] - Accounts payable decreased to ¥142,872,558.90, down 31.67% from ¥209,334,956.57 [9] - The non-current assets totaled ¥613,613,719.38, slightly down from ¥617,962,504.18, indicating a decrease of 0.56% [8]